Physician Assistant Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Emma Edwards

Physician Assistant, Medical Lincoln, NE Physician Assistant

NPI 1023356425 CMS profile 4479497

7121 Stephanie Ln Ste 102, Lincoln, NE 68516

Open in the dashboard

General payments

$7,562

305 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Emma Edwards of Lincoln, NE is reported in the CMS Open Payments database as having received $7,562 across 305 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,187 51
2024 General $1,120 57
2023 General $3,229 82
2022 General $1,026 59
2021 General $982 55
2020 General $18 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Emma Edwards
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Emma Edwards were reported at $1,187. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Emma Edwards Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $18 $20 $14–$64 $114
2021 $982 $156 $41–$563 $132
2022 $1,026 $185 $55–$649 $149
2023 $3,229 $199 $58–$717 $160
2024 $1,120 $206 $62–$740 $164
2025 $1,187 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Nevro Corp. $2,398 29 payments
  2. AbbVie, Inc. $1,417 77 payments
  3. Lundbeck LLC $434 22 payments
  4. Collegium Pharmaceutical, Inc. $423 25 payments
  5. Lilly USA, LLC $396 33 payments
  6. Pfizer Inc. $319 17 payments
  7. Abbott Laboratories $267 11 payments
  8. Globus Medical, Inc. $204 3 payments
  9. Scilex Pharmaceuticals Inc. $157 8 payments
  10. GRT US Holding, Inc. $154 7 payments
  11. Other $1,393 73 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $5,749 297 payments
  2. Education $1,010 6 payments
  3. Travel and Lodging $803 2 payments
Products named General payments · program years 2020–2025
  1. Senza Spinal Cord Stimulator $1,778 6 payments
  2. QULIPTA $834 40 payments
  3. UBRELVY $731 43 payments
  4. Senza Spinal Cord Stimulator $576 20 payments
  5. EMGALITY $396 33 payments
  6. BELBUCA $345 20 payments
  7. NURTEC ODT $319 17 payments
  8. ZAVZPRET $293 16 payments
  9. VYEPTI $238 11 payments
  10. Senza Spinal Cord Stimulator $204 3 payments
  11. Other $2,869 156 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

3,495

Median for Physician Assistant: 241

Drug cost

$206,718

Median for Physician Assistant: $4,110

Branded share of claims

25.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belbuca Buprenorphine Hcl Brand 78 $72,435
Buprenorphine Generic 191 $52,408
Pregabalin Generic 545 $11,463
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 468 $11,265
Duloxetine Hcl Generic 451 $8,973
Butrans Buprenorphine Brand 19 $7,630
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 55 $6,843
Gabapentin Generic 448 $5,723
Movantik Naloxegol Oxalate Brand 12 $5,068
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 154 $4,490

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$62,967

Of which drugs: $3,940

Medicare patients

569

Average age 75

Services billed

3,766

373 women, 196 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 31%
Chronic kidney disease 30%
Ischemic heart disease 28%
Diabetes 25%
Osteoporosis 22%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 46 2,181 $224
Injection, methylprednisolone acetate, 40 mg J1030 Office 11 15 $40
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 41 188 $15

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $173
$173 — —
EMGALITY
  • Lilly USA, LLC $136
$136 — —
BELBUCA
  • Collegium Pharmaceutical, Inc. $106
$106 78 —
VYEPTI
  • Lundbeck LLC $91
$91 — —
UBRELVY
  • AbbVie, Inc. $85
$85 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

305 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Nebraska

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record